Drugs / ZE63-0302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07234864 | Nov 2025 → Apr 2026 overdue | type 2 diabetes mellitus | Eilean Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06780124 | Apr 2024 → Jun 2025 | — | Eilean Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-11 | Eilean Therapeutics | EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR eileanther.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZE63-0302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07234864 ↗ |
| Route | Oral | “ZE63-0302 administered orally in healthy volunteers” NCT06780124 ↗ |